Drug intelligence / Profile preview

h11C5

Development stage: Unknown
Lead developer: 23andMe, Inc.
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

h11C5: sourced facts only. name: "11C5(Hy) murine 11C5 (“m11C5”), chimeric 11C5 (“c11C5”), humanized 11C5 mAb (“h11C5”)" [1] target: "the humanized anti-hu-IL1 RAP antibody, h11C5" [1] developer: "23andMe Inc." [1] modality: "humanized 11C5 mAb (“h11C5”)" [1]

Targets

IL1RAP (Interleukin 1 receptor accessory protein)

Beyond the preview

Go deeper on h11C5.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on h11C5.